The Centers for Medicare and Medicaid Services (CMS) announced that two manufacturers of sickle cell disease treatments will participate in the Center for Medicaid and Medicaid Innovation (CMMI) Cell and Gene Therapy (CGT) Access Model. Additional details follow. Manufacturer Participants: CMS details that bluebird bio, Inc., which manufactures LYFGENIA™, and Vertex Pharmaceuticals, which manufacture CASGEVYTM, have entered into agreements with… (Slifer, December 4, 2024) #Demonstration Programs, #Drug Pricing, #Prescription Drugs